Accelerates “clinic-ready” pediatric oncology therapies into Phase 1–2 trials, emphasizing high-need indications (e.g., high-risk/relapsed/metastatic, AYA) with clear milestones; up to USD 2,500,000 over three years.
Eligibility Criteria:
-
PI at a nonprofit academic/research institution (worldwide) or a small, privately held startup/biotech/pharma; doctoral degree required. Collaborative academia–industry projects encouraged.
-
Projects must be IND-ready, under an active IND (or equivalent), or adult-approved agents not yet studied in pediatric oncology.
-
If requesting ≥ USD 500,000, PI effort ≥10%. No active CureSearch grant in the same cycle.
Funding Details:
-
Up to USD 2,500,000 total (≤3 years), including up to 10% indirect costs. NIH salary cap applies; equipment ≤20% of direct costs; travel ≤ USD 5,000/year; no tuition/visa/professional dues. Payments biannual for academics; for-profits may use milestone/equity schedules.
-
Expected milestones: first patient enrolled year 1; accrual complete year 2; manuscript submitted by end of year 3.
Deadline:
-
LOI due: October 7, 2025 (11:59 p.m.)
-
LOI decisions/invites: November 10, 2025
-
Full application due: January 18, 2026
-
Earliest award notice: March 2026 (rolling, funds permitting).
Where to Go for Further Information:
-
Submit LOI via ProposalCentral.
-
Program questions: [email protected].